| Autor: |
Aradhyula V; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Vyas R; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Dube P; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Haller ST; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Gupta R; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Maddipati KR; Department of Pathology, Lipidomics Core Facility, Wayne State University, Detroit, Michigan, United States., Kennedy DJ; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States., Khouri SJ; Department of Medicine, University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, United States. |
| Abstrakt: |
Heart failure (HF) with preserved ejection fraction (HFpEF) is the most common cause of pulmonary hypertension (PH) worldwide and is strongly associated with adverse clinical outcomes. The American Heart Association recently highlighted a call to action regarding the distinct lack of evidence-based treatments for PH due to poorly understood pathophysiology of PH attributable to HFpEF (PH-HFpEF). Prior studies have described cardiophysiological mechanisms to explain the development of isolated postcapillary PH (ipc-PH); however, the consequent increase in pulmonary vascular (PV) resistance (PVR) may lead to the less understood and more fatal combined pre- and postcapillary PH (cpc-PH). Metabolic disease and inflammatory dysregulation have been suggested to predispose PH, yet the molecular mechanisms are unknown. Although PH-HFpEF has been studied to partly share vasoactive neurohormonal mediators with primary pulmonary arterial hypertension (PAH), clinical trials that have targeted these pathways have been unsuccessful. The increased mortality of patients with PH-HFpEF necessitates further study into viable mechanistic targets involved in disease progression. We aim to summarize the current pathophysiological and clinical understanding of PH-HFpEF, highlight the role of known molecular mechanisms in the progression of PV disease, and introduce a novel concept that lipid metabolism may be attenuating and propagating PH-HFpEF. NEW & NOTEWORTHY Our review addresses pulmonary hypertension (PH) attributable to heart failure (HF) with preserved ejection fraction (HFpEF; PH-HFpEF). Current knowledge gaps in PH-HFpEF pathophysiology have led to a lack of therapeutic targets. Thus, we address identified knowledge gaps in a comprehensive review, focusing on current clinical epidemiology, known pathophysiology, and previously studied molecular mechanisms. We also introduce a comprehensive review of polyunsaturated fatty acid (PUFA) lipid inflammatory mediators in PH-HFpEF. |
